explore -WSS

explore

author：fashion 2025-09-02 08:14:55 - browse：64

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Dana Farber says 6 studies to be retracted and 31 corrected

focus

WSS

Maisha Meds is a PBM, but don't call it that

The biotech scorecard for Q4: 16 stock

Health insurers' Q3 question: how much care are people getting?

HPV vaccine, cervical cancer study delivers historic results

New oral drug delivery patch is modeled after octopus tentacles

Congress extends some pandemic preparedness programs

leisure time

explore

hotspot

Guidelines to prevent youth baseball injuries need more muscle

CDC picks Alphabet's Verily for wasterwater surveillance contract

Heart attack and stroke risk calculators need revising

Stop Congress from blocking public access to science

Activists slam private health insurers over coverage restrictions

What will Novo Nordisk's VC do with its influx of cash?

Affirmative action in medical school literally saved lives

The biotech scorecard for Q4: 16 stock

Alkermes shareholders re

FDA sets aggressive timeline for overhauling inspection procedures

knowledge

Medicare drug price lawsuits could be good politics for Biden

Head of FDA's diagnostics center, who led through Covid, retires

FDA endorses new sterilization method for medical devices

6 solutions to address cancer drug shortages and others

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Pumping milk in bathrooms at health conferences is common

leisure time

focus

explore

knowledge